AC-P19M

General Information


DRACP ID  DRACP04527

Peptide Name   AC-P19M

Sequence  FAKKLAKLKKKLAKLAKKR

Sequence Length  19

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C105H195N31O20

Absent amino acids  CDEGHIMNPQSTVWY

Common amino acids  K

Mass  253316

Pl  12.21

Basic residues  10

Acidic residues  0

Hydrophobic residues  9

Net charge  10

Boman Index  -3497

Hydrophobicity  -75.79

Aliphatic Index  103.16

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity

Doi Not available

Year  2022

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  20465

DRACP is developed by Dr.Zheng's team.